ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
- Mechanism
- Curator reviewed
With Multiple Sclerosis, excessive amounts of VLA-4 are believed to mediate the inappropriate migration of lymphocytes into the central nervous system, contributing to the pathogenesis of the disease. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby halting progression of the disease. The mechanism of action of ATL1102 in blocking VLA-4 isdifferent to other drugs in development that target this same protein,including the monoclonal antibody Tysabri(R).
- Primary indication
- Investigated for use/treatment in asthma and multiple sclerosis.Curator reviewed
- Code names
- ATL-1102
Resolves to
What you can answer from here — as of September 15, 2023
Which drugs share a target with ATL1102, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account